Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
暂无分享,去创建一个
E. Ricevuto | E. Jannini | V. Tombolini | V. Dolo | G. Gravina | C. Festuccia | S. Di Sante | F. Marampon | E. Carosa | I. Giusti
[1] W. Oh,et al. PC3 is a cell line characteristic of prostatic small cell carcinoma , 2011, The Prostate.
[2] D. Sherris,et al. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. , 2011, Endocrine-related cancer.
[3] K. Kuroiwa,et al. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells , 2011, The Prostate.
[4] E. Ricevuto,et al. Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. , 2009, International journal of oncology.
[5] S. Fulda,et al. Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8 , 2009, Oncogene.
[6] H. Prince,et al. Clinical Studies of Histone Deacetylase Inhibitors , 2009, Clinical Cancer Research.
[7] L. Borsu,et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.
[8] W. Hahn,et al. The current state of preclinical prostate cancer animal models , 2008, The Prostate.
[9] R. Rees,et al. DNA demethylation and histone deacetylation inhibition co‐operate to re‐express estrogen receptor beta and induce apoptosis in prostate cancer cell‐lines , 2008, The Prostate.
[10] P. Finn,et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.
[11] D. Qian,et al. Antitumor activity of the histone deacetylase inhibitor MS‐275 in prostate cancer models , 2007, The Prostate.
[12] M. Sehested,et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo , 2007, Cancer Chemotherapy and Pharmacology.
[13] C. Van Waes,et al. Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 , 2007, Molecular Cancer Therapeutics.
[14] M. Sehested,et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies , 2006, Molecular Cancer Therapeutics.
[15] M. Carducci,et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. , 2006, Cancer research.
[16] B. Aggarwal,et al. Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-κB Activation* , 2006, Journal of Biological Chemistry.
[17] Michele Caraglia,et al. Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo , 2006, Clinical Cancer Research.
[18] Z. Malik,et al. In vivo and in vitro antitumor activity of butyroyloxymethyl‐diethyl phosphate (AN‐7), a histone deacetylase inhibitor, in human prostate cancer , 2005, International journal of cancer.
[19] Hee June Choi,et al. Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes , 2005, Nature.
[20] Hing Y Leung,et al. Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.
[21] D. Neal,et al. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. , 2004, European urology.
[22] D. Leroith,et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.
[23] Rakesh Kumar,et al. Emerging roles of MTA family members in human cancers. , 2003, Seminars in oncology.
[24] P. Finn,et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.
[25] C. Tepper,et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.
[26] Angie Rizzino,et al. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. , 2002, Carcinogenesis.
[27] Lee M Ellis,et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] R. Dahiya,et al. Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.
[29] Jian Zhang,et al. Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro , 2001, The Prostate.
[30] K. Pienta,et al. VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.
[31] E. Baldi,et al. Androgen Receptor Expression in Prostate Carcinoma Cells Suppresses α6β4 Integrin-Mediated Invasive Phenotype. , 2000, Endocrinology.
[32] W. D. Cress,et al. Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.
[33] Noah Craft,et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.
[34] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[35] W. Oh,et al. PC 3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma , 2012 .
[36] W. Gerald,et al. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. , 2009, American journal of translational research.
[37] M. Motta,et al. Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. , 2003, Oncology research.
[38] F. Dequiedt,et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.
[39] Bernhard O. Palsson,et al. Cancer cell lines , 1999 .